Literature DB >> 34431082

Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project.

Sherif M Badawy1,2, Amanda B Payne3, Mary M Hulihan3, Thomas D Coates4, Suvankar Majumdar5, Dominic Smith6, Alexis A Thompson1,2.   

Abstract

Entities:  

Keywords:  hepatitis; iron overload; sickle cell disease; thalassaemia; vaccines

Mesh：

Substances：

Year:  2021        PMID： 34431082      PMCID： PMC8627444          DOI： 10.1111/bjh.17798

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   8.615


× No keyword cloud information.
  11 in total

1.  Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Authors:  Janet L Kwiatkowski; Hae-Young Kim; Alexis A Thompson; Charles T Quinn; Brigitta U Mueller; Isaac Odame; Patricia J Giardina; Elliott P Vichinsky; Jeanne M Boudreaux; Alan R Cohen; John B Porter; Thomas Coates; Nancy F Olivieri; Ellis J Neufeld
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

Review 2.  Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.

Authors:  Maria Marsella; Caterina Borgna-Pignatti
Journal:  Hematol Oncol Clin North Am       Date:  2014-08       Impact factor: 3.722

Review 3.  Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.

Authors:  Michael Evangeli; Kulsoom Mughal; John B Porter
Journal:  Hemoglobin       Date:  2010-06       Impact factor: 0.849

4.  A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.

Authors:  Sherif M Badawy; Usman Beg; Robert I Liem; Sonali Chaudhury; Alexis A Thompson
Journal:  Blood Adv       Date:  2021-01-26

5.  Challenges of adherence and persistence with iron chelation therapy.

Authors:  John B Porter; Michael Evangeli; Amal El-Beshlawy
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

6.  Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.

Authors:  Sherif M Badawy; Robert I Liem; Cynthia K Rigsby; Richard J Labotka; R Andrew DeFreitas; Alexis A Thompson
Journal:  Br J Haematol       Date:  2016-08-10       Impact factor: 6.998

Review 7.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

8.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

9.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-06-28       Impact factor: 17.586
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.